Aardvark Therapeutics Inc (NASDAQ:AARD) shares, rose in value on Wednesday, June 18, with the stock price up by 7.19% to the previous day’s close as strong demand from buyers drove the stock to $12.08.
Actively observing the price movement in the last trading, the stock closed the session at $11.27, falling within a range of $11.46 and $12.13. Referring to stock’s 52-week performance, its high was $19.58, and the low was $4.88. On the whole, AARD has fluctuated by 15.82% over the past month.
With the market capitalization of Aardvark Therapeutics Inc currently standing at about $262.08 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-14.
The stock’s technical analysis shows that the price of AARD currently trading nearly 9.13% and 20.78% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 60.57, while the 7-day volatility ratio is showing 4.20% which for the 30-day chart, stands at 4.33%. Furthermore, Aardvark Therapeutics Inc (AARD)’s average true range (ATR) is 1.08.
Data on historical trading for Aardvark Therapeutics Inc (NASDAQ:AARD) indicates that the trading volumes over the past 10 days have averaged 35490.0 and over the past 3 months, they’ve averaged 78.97K. According to company’s latest data on outstanding shares, there are 21.69 million shares outstanding.
Nearly 42.89% of Aardvark Therapeutics Inc’s shares belong to company insiders and institutional investors own 21.98% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.34 million shares as on 2025-05-30, resulting in a short ratio of 6.07. According to the data, the short interest in Aardvark Therapeutics Inc (AARD) stood at 243.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 0.32 million. The stock has fallen by -15.58% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AARD stock heading into the next quarter.
